Onate, G, Pratcorona M., Garrido A., Artigas-Baleri A., Bataller A., Tormo M., Arnan M., Vives S., Coll R., Salamero O., Vall-Llovera F., Sampol A., Garcia A., Cervera M., Avila S.G., Bargay J., Ortín X., Nomdedéu J.F., Esteve J., Sierra J.. Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Blood Cancer Journal. 2023; 13(1)DOI:10.1038/s41408-023-00839-1. PMID:37147301. IF:12.900(Q1/1D).

Pinana, JL, Martino, R, Vazquez, L, Lopez-Corral, L, Perez, A, Chorao, P, Avendano-Pita, A, Pascual, MJ, Sanchez-Salinas, A, Sanz-Linares, G, Olave, MT, Arroyo, I, Tormo, M, Villalon, L, Conesa-Garcia, V, Gago, B, Terol, MJ, Villalba, M, Garcia-Gutierrez, V, Cabero, A, Hernandez-Rivas, JA, Ferrer, E, Garcia-Cadenas, I, Teruel, A, Navarro, D, Cedillo, A, Sureda, A, Solano, C. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. BONE MARROW TRANSPLANTATION. 2023; 58(5)DOI:10.1038/s41409-023-01946-0. PMID:36854892. IF:4.500(Q1/2D).

Velao, SR, Cadenas, IG, Cuesta, MA, Sanchez-Ortega, I, Fernandez-Aviles, F, Roldan, E, Torrent, A, Viguria, MC, Villar, S, Bento, L, Yanez, L, Martino, R, Pinana, JL. Low rate of infectious enterocolitis in allogeneic stem cell transplant recipients with acute diarrhea: A prospective study by the GETH-TC.. ACTA HAEMATOLOGICA. 2023; 146(2)DOI:10.1159/000528242. PMID:36446336. IF:1.700(Q3/8D).

Mussetti, A, Bento, L, Bastos-Oreiro, M, Rius-Sansalvador, B, Albo, C, Bailen, R, Barba, P, Benzaquen, A, Briones, J, Caballero, AC, Campos, A, Espanol, I, Ferra, C, Lopez, SG, Sierra, PAG, Guerra, LM, Hernani, R, Iacoboni, G, Jimenez-Ubieto, A, Kwon, M, Corral, LL, Lopez-Godino, O, Munoz, MCM, Martinez-Cibrian, N, Gomez, JM, Perez-Ortega, L, Orti, G, Ortiz-Maldonado, V, Pascual, MJ, Perera, M, Perez, A, Reguera, JL, Sanchez, JM, Sanz, J, Torrent, A, Yanez, L, Varela, R, Echechipia, IC, Caballero, D, Sureda, A. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Mar, 10.1038/s41409-023-01949-x, 2023). BONE MARROW TRANSPLANTATION. 2023; 58(6)DOI:10.1038/s41409-023-01967-9. PMID:37076611. IF:4.500(Q1/2D).

Crees, ZD, Rettig, MP, Jayasinghe, RG, Stockerl-Goldstein, K, Larson, SM, Arpad, I, Milone, GA, Martino, M, Stiff, P, Sborov, D, Pereira, D, Micallef, I, Moreno-Jimenez, G, Mikala, G, Coronel, MLP, Holtick, U, Hiemenz, J, Qazilbash, MH, Hardy, N, Latif, T, Garcia-Cadenas, I, Vainstein-Haras, A, Sorani, E, Gliko-Kabir, I, Goldstein, I, Ickowicz, D, Shemesh-Darvish, L, Kadosh, S, Gao, F, Schroeder, MA, Vij, R, DiPersio, JF. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. NATURE MEDICINE. 2023; 29(4)DOI:10.1038/s41591-023-02273-z. PMID:37069359. IF:58.700(Q1/1D).

Perl A.E., Larson R.A., Podoltsev N.A., Strickland S., Wang E.S., Atallah E., Schiller G.J., Martinelli G., Neubauer A., Sierra J., Montesinos P., Recher C., Yoon S.-S., Maeda Y., Hosono N., Onozawa M., Kato T., Kim H.-J., Hasabou N., Nuthethi R., Tiu R., Levis M.J.. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplantation And Cellular Therapy. 2023; 29(4)DOI:10.1016/j.jtct.2022.12.006. PMID:36526260. IF:3.600(Q1/3D).